Skip to main content
. 2022 Jan 28;13(11):3147–3160. doi: 10.1039/d1sc05243h

Fig. 2. Pharmacokinetic analysis of high-DAR maytansinoid TXC (αHer2/XTEN-May16) versus XTENylated antibody lacking payloads (αHer2/XTEN), low-DAR TDC (αHer2/May2), and THIOMAB antibody control (αHer2). Concentrations measured are normalized to the molar doses of each conjugate.

Fig. 2